Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Gilead Sciences presented findings from several studies of the single-tablet antiretroviral regimen at a recent scientific meeting.
Research in human cells and mice found the antiretroviral suppressed harmful chronic inflammation linked to age-related disorders.
Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) includes Pifeltro (doravirine) in a three-drug single-tablet regimen.
Researchers conducted a systematic review of antiretroviral treatment outcomes since 1994 among 78,000 people with HIV.
Compared with a regimen based on Prezista, doravirine was better for blood lipids, including cholesterol and triglycerides.
This finding came from a larger report indicating that U.S. residents are increasingly taking drugs linked to such symptoms.
In a randomized comparison trial, those who switched from Epzicom to Descovy had a comparable rate of HIV suppression.
A recent study of Dutch clinicians found that they generally did a good job of preventing drug-drug interactions.
Highlights from HIV and hepatitis C research presented at the 2018 Conference on Retroviruses and Opportunistic Infections (CROI) in Boston
Forty-eight-week results are in from a Phase III study that switched participants from Triumeq to Gilead’s new single-tablet regimen.
The once-daily regimen includes the integrase inhibitor bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).
In four studies, this two-drug combination suppressed the virus as effectively as staying on a three-drug regimen.
A tablet containing bictegravir and the contents of Descovy suppressed HIV as well as boosted protease inhibitor regimens.
The single-tablet regimen includes the experimental bictegravir plus the contents of Descovy (emtricitabine/tenofovir alafenamide).
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.